Compare American Electric Power Company Inc (AEP) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Electric Power Company Inc vs BridgeBio Pharma Inc — how do they compare? American Electric Power Company Inc trades at $135.88 (market cap $74.83B), while BridgeBio Pharma Inc trades at $78.11 (market cap $15.26B). The key difference: American Electric Power Company Inc is far larger — about 4.9× BridgeBio Pharma Inc's market cap, and American Electric Power Company Inc pays a 2.76% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AEP | BBIO | |
|---|---|---|
Market Cap | $74.83B | $15.26B |
Sector | Utilities | Health |
52-Week High | $138.69 | $79.91 |
52-Week Low | $103.96 | $43.19 |
Enterprise Value | $126.09B | $16.81B |
Dividend Yield | 2.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $137.53, down 0.71% on the day, with strong analyst support (64% buy ratings) and a $142.82 consensus price target. The stock shows bullish technical momentum with recent earnings beats and robust revenue growth, climbing from $19.7B in 2024 to $21.9B in 2025. AEP benefits from AI-driven electricity demand and a $78B capital plan for grid expansion.
Outlook remains positive given AEP's strategic positioning in energy infrastructure, though risks include high capital expenditures and debt levels. The current valuation at 20.12x P/E appears reasonable for a utility with stable earnings growth and dividend payments, supporting a constructive view for long-term investors.
BridgeBio Pharma (BBIO) trades at $77.91, up 0.93% on the day, supported by a bullish technical outlook and strong analyst consensus. The stock shows robust revenue growth, with 2025 revenue reaching $502.08M, though it remains unprofitable with a net income margin of -124.41%. Recent positive news includes a $1 billion preferred equity raise and regulatory progress for key drug candidates, fueling investor optimism despite ongoing cash burn from operations.
The investment case hinges on the company's pipeline catalysts and commercial execution, with a consensus price target of $102.75 implying significant upside. However, high cash burn, negative equity, and consistent earnings misses present substantial risks, requiring careful monitoring of upcoming clinical and regulatory milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
